If the initial data of the current Phase III study is positive, the company believes initial approval could be granted before the end of 2021. The Valneva COVID-19 vaccine pursues a conventional approach with inactivated viruses.
Valneva will gather immunogenicity data of its inactivated whole virus vaccine VLA2001 for 150 people who are older than the age of 56. In another part involving 600 participants in a Cov-Compare study at ten testing sites in New Zealand, volunteers aged twelve will receive VLA2001 and a vaccine candidate named VLA2101 on the basis of a virus variant.
Continue reading and learn more about life sciences research in Austria!